Short answer
ResMed (RMD) filed its Q1 2025 10-Q quarterly report on Apr 24, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $1.3B (up 7.9% year over year) with net income of $365M.
Q1 2025 key financials · XBRL
- Revenue
- $1.3B
- +7.9% YoY · +0.8% QoQ
- Net income
- $365M
- +21.5% YoY · +5.9% QoQ
- Operating margin
- 33.0%
- Gross margin
- 59.3%
- EPS (diluted)
- $2.48
- +21.6% YoY · +6.0% QoQ
Source: XBRL data from the ResMed (RMD) Q1 2025 10-Q on SEC EDGAR. USD.
ResMed Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: U.S. tariffs on imports from Canada, Mexico, China triggered retaliatory trade measures impacting sourcing costs and revenue
- Updated macroeconomic risk: Recent Red Sea shipping disruptions added to inflation, currency, and capital market volatility affecting supply chain and demand
- Regulatory risk: Potential new international trade laws could increase cost of goods exported, raise effective tax rate, and materially hurt financial condition
- Operational risk: Supply chain constraints on raw materials and components causing higher costs, minimum purchase obligations, upfront payments, and production delays
- Market risk: Deteriorating global economy may reduce product demand, lower prices, and reduce reimbursement rates by third-party payors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ResMed quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.